压电(QCM)生物传感器 2011

The chondroitin sulfate A-binding site of the VAR2CSA protein involves multiple N-terminal domains.

The Journal of biological chemistry Dahlbäck M, Jørgensen LM, Nielsen MA, Clausen TM, Ditlev SB, Resende M, Pinto VV, Arnot DE, Theander TG, Salanti A
阅读原文 PDF DOI PubMed

组成图示

The chondroitin sulfate A-binding sit... 传感器构成示意图

点击图片查看大图 · 依据论文自动绘制

传感器类型

压电(QCM)生物传感器

检测对象

VAR2CSA重组蛋白片段(VAR2CSA recombinant fragments,如FV2、NTS-FV2、DBL2X-CIDRPAM等),样品基质为PBS缓冲液

检测原理

传感器以金镀AT-cut石英晶体为压电换能器,表面经聚苯乙烯预处理后吸附CSPG或HSPG,并用0.1%无免疫球蛋白BSA封闭。PBS中不同浓度的VAR2CSA重组片段流经表面,其N端结构域与CSPG上的CSA链发生特异性结合,使晶体表面质量增加,按Sauerbrey效应引起共振频率下降。通过连续监测结合与解离相,获得sensorgram;对多浓度数据拟合1:1或异质性模型,得到kon、koff和KD。信号大小反映结合质量与亲和力,HSPG作为对照用于评估特异性。

检测灵敏度

未报告LOD、线性范围、灵敏度斜率或R^2;报告结合常数KD: 0.54 nM (FV2)、2.9 nM (NTS-FV2)、40 nM (DBL2X-CIDRPAM)、2.7 nM (DBL1X-CIDRPAM)、0.86 nM (ID1-DBL3X)。

效应效果

QCM与固相结合实验一致显示,含DBL2X-CIDRPAM核心并带DBL1X或DBL3X侧翼的片段对CSPG呈高特异性结合,而对HSPG峰响应明显较低;DBL2X-CIDRPAM单独结合CSPG与HSPG水平相近,特异性不足,且所有蛋白均不结合硫酸软骨素酶ABC处理后的CSPG蛋白核心。动物免疫IgG中,DBL4β-ID4和NTS-FV2抗体在0.5 mg/mL完全阻断、0.1 mg/mL抑制>90%;NTS-DBL3X抗体在0.5 mg/mL抑制>90%,而单个结构域抗体混合无阻断活性。结果支持N端最小结合区作为妊娠疟疾疫苗靶点。

传感器的构成

  • 换能器基底:金镀层10 MHz AT-cut石英晶体,作为QCM压电换能器并产生频率响应
  • 表面预处理层:聚苯乙烯涂层(polystyrene coating),提供蛋白吸附表面
  • 捕获识别层:CSPG(decorin,含CSA链)或HSPG,100 µg/mL PBS室温吸附30 min,用于捕获VAR2CSA
  • 封闭层:PBS含0.1%无免疫球蛋白BSA(Ig-free BSA),封闭非特异性结合位点
  • 流动池体系:圆柱形流动池(1.25 µl),PBS运行缓冲液,25 µl/min、25 °C,维持结合与解离环境
  • 信号读出:Attana A100 QCM生物传感器,监测结合质量变化引起的频率变化(Hz)

中文摘要

妊娠疟疾是非洲妇女的重大健康问题,由恶性疟原虫感染红细胞黏附于胎盘硫酸软骨素A(CSA)引起。感染红细胞与胎盘受体之间的相互作用由寄生虫表达的VAR2CSA蛋白介导。保护孕妇的疫苗应诱导能抑制VAR2CSA与CSA相互作用的抗体。全长重组VAR2CSA可高亲和力特异性结合CSA,但迄今尚无亚片段表现出相似亲和力或特异性。本研究利用生物传感器技术系统检测一系列截短VAR2CSA蛋白的结合特性,结果表明CSA结合位点核心位于N端三个结构域DBL2X-CIDRPAM及一个相邻结构域中。含有该区域的重组VAR2CSA亚片段在动物免疫实验中可诱导具有高效寄生虫黏附阻断活性的抗体,为妊娠疟疾疫苗设计提供了关键依据。

英文摘要

Malaria during pregnancy is a major health problem for African women. The disease is caused by Plasmodium falciparum malaria parasites, which accumulate in the placenta by adhering to chondroitin sulfate A (CSA). The interaction between infected erythrocytes and the placental receptor is mediated by a parasite expressed protein named VAR2CSA. A vaccine protecting pregnant women against placental malaria should induce antibodies inhibiting the interaction between VAR2CSA and CSA. Much effort has been put into defining the part of the 350 kDa VAR2CSA protein that is responsible for binding. It has been shown that full-length recombinant VAR2CSA binds specifically to CSA with high affinity, however to date no sub-fragment of VAR2CSA has been shown to interact with CSA with similar affinity or specificity. In this study, we used a biosensor technology to examine the binding properties of a panel of truncated VAR2CSA proteins. The experiments indicate that the core of the CSA-binding site is situated in three domains, DBL2X-CIDR(PAM) and a flanking domain, located in the N-terminal part of VAR2CSA. Furthermore, recombinant VAR2CSA subfragments containing this region elicit antibodies with high parasite adhesion blocking activity in animal immunization experiments.